Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Journal of Pharmaceutical and Sciences.
Adhwa'a Kaylla
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Nursing Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Interaksi Warfarin dan Aspirin terhadap Risiko Perdarahan pada Pasien Penderita Penyakit Kardiovaskular Subekti, Firli Reisya; Nurhafidah, Zahra; Saputri, Jasmine Rahma; Adhwa'a Kaylla; Shadrina, Jahra Almas; Maharani, Puteri Rahma; Putri, Mukarromah Dita; Sudarjat, Hadi; Hilmi, Indah Laily
Journal of Pharmaceutical and Sciences JPS Volume 9 Nomor 1 (2026)
Publisher : Fakultas Farmasi Universitas Tjut Nyak Dhien

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36490/journal-jps.com.v9i1.1196

Abstract

Background: Cardiovascular disease (CVD) remains a leading cause of global morbidity and mortality; therefore, antithrombotic therapy such as warfarin and aspirin plays a crucial role in preventing thromboembolic events. The combination of these two agents provides a synergistic effect in inhibiting thrombus formation but significantly increases the risk of bleeding. Objective: To evaluate the impact of concominant ose of warfarin and aspirin on bleeding risk and its clinical benefits in patients with CVD. Methods: A systematic literature search was conducted using Google Scholar and Pubmed, with eligible studies analyzed. Result: The concomitant use of warfarin and aspirin increases the incidence of major bleeding without providing additional benefits in preventing stroke or myocardial infarction. Moreover, poor anticoagulation control further exacerbates this risk. Conclusion: The combination of warfarin and aspirin should be reserved only for patients with strong clinical indications, while warfarin monotherapy is safer for those with stable conditions. These findings emphasize the importance of individualized therapy evaluation and optimal INR monitoring to balance therapeutic benefits and bleeding risks.
Co-Authors Indah Laily Hilmi Maharani, Puteri Rahma Nurhafidah, Zahra Putri, Mukarromah Dita Saputri, Jasmine Rahma Shadrina, Jahra Almas Subekti, Firli Reisya Sudarjat, Hadi